We sought to investigate the incidence of sarcopenia and its impact on main oncological outcomes in patients with muscle invasive bladder cancer (MIBC) treated with trimodal therapy (TMT).
This was a retrospective analysis of 141 MIBC patients treated with TMT in the period 2002 to 2018.